Daclizumab is a therapeutic humanized monoclonal antibody targeting CD25 to abolish high-affinity IL2-R, which was once approved for the treatment of adult MS owing to the promising clinical effects but has been withdrawn nowadays due to its severe adverse events [68, 76]. The gene discussed is IL2RA; the disease is myeloid sarcoma.